We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomedical Engineers Create Silk Microneedles for Controlled-Release Drug Delivery

By LabMedica International staff writers
Posted on 04 Jan 2012
A publication described the manufacture and use of biodegradable and biocompatible “microneedles” as a minimally invasive drug delivery alternative to hypodermic needles.

Microneedles, which are no more than a micrometer in size and able to penetrate the upper layer of the skin without reaching nerves, have been touted as a painless new drug delivery mechanism. More...
However, their development has been limited by complications ranging from harsh manufacturing requirements that destroy sensitive biological compounds, to the inability to precisely control drug release or deliver sufficient drug volume, to problems with infections caused by the small skin punctures.

In the current study, investigators at Tufts University (Medford MA, USA) described the use of silk fibroin for the production of microneedles. Silk fibroin combines excellent mechanical properties, biocompatibility, biodegradability, benign processing conditions, and the ability to preserve and maintain the activity of biological compounds entrained in its material matrix. The degradation rate of silk fibroin and the diffusion rate of the entrained molecules can be controlled simply by adjusting postprocessing conditions.

The process described in the December 2, 2011, online edition of the journal Advanced Functional Materials was based on conditions of ambient pressure and temperature and aqueous processing. Aluminum microneedle molding masters were fabricated into needle arrays of about 500 micron needle height and tip radii of less than 10 microns. The elastomer polydimethylsiloxane (PDMS) was cast over the master to create a negative mold; a drug-loaded silk protein solution was then cast over the mold. Further processing through water vapor annealing, and mechanical and electronic exposures at various temperatures provided control over the permeability of the silk microneedles and their drug release kinetics.

Results showed that silk microneedles could deliver simultaneously a large-molecule, enzymatic model drug (horseradish peroxidase), and the antibiotic tetracycline at controlled rates while maintaining bioactivity.

“By adjusting the postprocessing conditions of the silk protein and varying the drying time of the silk protein, we were able to precisely control the drug release rates in laboratory experiments,” said senior author Dr. Fiorenzo Omenetto, professor of biomedical engineering at Tufts University. “The new system addresses long-standing drug delivery challenges, and we believe that the technology could also be applied to other biological storage applications.”

Related Links:
Tufts University


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.